We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Potential Cure for Rheumatoid Arthritis Succeeds in Mouse Model

By LabMedica International staff writers
Posted on 10 Feb 2010
Researchers working with a mouse model of rheumatoid arthritis have identified a molecule with the potential to act as a chemotherapeutic agent for treatment of this devastating autoimmune disorder.

Investigators at Northwestern University (Chicago, IL, USA) worked with a line of mice that had been genetically engineered to lack the gene for a protein called Bim, an agent that mimics the action of Bcl-2 homology 3 (BH3) domain-only proteins. More...
Such proteins have shown promise in preclinical studies of cancer and autoimmune disease treatment.

The expression of Bim was found to be reduced in synovial tissue from human rheumatoid arthritis patients as compared with controls, particularly in macrophages. Macrophages from mice lacking the Bim gene displayed elevated expression of inflammatory markers following stimulation with LPS (lipopolysaccharide) or thioglycollate.

In the current study, the investigators induced rheumatoid arthritis in mice lacking Bim expression. They reported in the February 2010 issue of the journal Arthritis & Rheumatism that treatment of these animals with exogenous Bim ameliorated rheumatoid arthritis symptoms. Furthermore, treatment with Bim prior to induction of arthritis prevented development of symptoms of the disease.

"This new therapy stopped the disease cold in 75% of the mice," said senior author Dr. Harris Perlman, associate professor of medicine at Northwestern University. "The best part was we did not see any toxicity. This has a lot of potential for creating an entirely new treatment for rheumatoid arthritis. The next step is to develop nanotechnology for a more precise method of delivering the drug."

Related Links:

Northwestern University



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Pipette Calibration System
Artel PCS®
New
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The method that profiles DNA methylation in cell-free DNA from a single blood sample to detect disease signals system-wide (photo courtesy of Shutterstock)

cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample

Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read more

Immunology

view channel
Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.